[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fCZHPxcuN6K6YaNxjOc7e29jDtfVOONvUQy1-9WagbaA":8,"$f87H2R7ivPWdkid-IvH0BE5hx1aMvkyWNLLOHBB_wKus":55,"$f9Sx-YIqTzP8ja_cylDEcmK5_CsQdI1UeTx9bCc3ELmc":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},74860,867271,[],"https://ystcdn.venuertc.com/medical/ystApp/1KNmXQDnP2XagGmzBK1qyfRfTWA6Qk1r.png","李浩齐","缙云县新建镇中心卫生院","全科医疗","住院医师",516,0,"结肠癌T3NxM1分期常用药品关键用法指南","","https://ystcdn.venuertc.com/venue/AI/c1d97018-862d-441c-bcc6-e8eb6c07fb54.jpg","\u003Cdiv id=\"material_title\" class=\"colonguide-title\">\n  \u003Ch1>结肠癌T3NxM1分期常用药品关键用法指南\u003C/h1>\n  \u003Cp class=\"colonguide-subtitle\">聚焦安全用药，掌握化疗与靶向治疗的7个细节\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f3f7fa 60%, #e8eef1 100%);\">\n    \u003Ch2>💊一、化疗药物的分类及作用机制\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      结肠癌T3NxM1分期常用的化疗方案包括FOLFIRI（含伊立替康）、XELOX（奥沙利铂+卡培他滨）以及靶向药品如贝伐珠单抗等。化疗药物主要通过阻断肿瘤细胞分裂和DNA修复过程来达到抑制细胞增殖的目的。以伊立替康为例，它属于拓扑异构酶Ⅰ抑制剂，可干扰DNA复制，影响细胞增殖。奥沙利铂则通过与DNA结合，阻断细胞分裂。靶向药品如贝伐珠单抗可抑制肿瘤新生血管发育，为联合方案提供支持。\n    \u003C/p>\n    \u003Cp class=\"colonguide-note\">引文：Van Cutsem, E., et al. (2016). ‘Evolving role of chemotherapy and targeted therapies in metastatic colorectal cancer’. Journal of Clinical Oncology, 34(9), 972-979.\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f6faf8 55%, #ecf1ef 100%);\">\n    \u003Ch2>⏰二、服药时间和用法细节\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      化疗药物通常需在专科医生指导下静脉注射或口服。像卡培他滨应于餐后30分钟内口服，以减少胃肠刺激。联合用药时各药物间的服用顺序需遵循医嘱，部分药品如奥沙利铂、伊立替康多通过输液使用，绝不可自行调整用药时间。正确做法：遵循固定周期、时间点，每次用药前确认剂量及方案，避免早晚颠倒或漏服。\n    \u003C/p>\n    \u003Cp>\n      有位57岁男性患者连续完成13周期化疗，每次严格按照医嘱定时用药，未出现明显用药失误，体现出规范周期用药的重要性。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f4f7fa 56%, #eaedee 100%);\">\n    \u003Ch2>💡三、剂型特点与使用技巧\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      常见剂型包括静脉注射液（伊立替康、奥沙利铂）、口服片剂（卡培他滨）、生物制剂（靶向药）。口服片剂需用足量水吞服，切勿嚼碎或掰断，否则可能影响药效和刺激胃肠道。静脉注射需专科护士操作，使用之前要核查溶液外观，有异色或沉淀不得使用。靶向药品如贝伐珠单抗需定期注射，不可自行更改剂型。\n    \u003C/p>\n    \u003Cp>\n      正确做法：口服片剂时建议用200px以上的水送服，注射用药前务必核查药液令避免杂质。\n    \u003C/p>\n    \u003Cp class=\"colonguide-note\">引文：Grothey, A., et al. (2018). ‘Chemotherapy and targeted therapy combinations for colorectal cancer’. Nature Reviews Clinical Oncology, 15, 409-424.\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f7faf8 62%, #ecefed 100%);\">\n    \u003Ch2>⚠️四、药物相互作用及用药搭配\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      多种化疗药物合用时，会有互相影响：伊立替康与某些抗生素（如红霉素类）同时使用可能增加不良反应；奥沙利铂与利尿剂并用有导致肾毒性的风险。因此，在化疗期间，所有药品（包括感冒药、保健品等）都应报备医生。靶向药物如贝伐珠单抗可能增加出血风险，搭配抗凝药时尤其要警惕。若须同时服用多种药品，须提前向医生申报，由医师协调服药时序。\n    \u003C/p>\n    \u003Cp>\n      数据表明，联合治疗方案可以提升疗效，但药物间作用复杂，绝不能擅自叠加药品。引文：Hurwitz, H., et al. (2004). ‘Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer’. New England Journal of Medicine, 350(23), 2335-2342.\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f8faf7 60%, #ebedec 100%);\">\n    \u003Ch2>👥五、特殊人群用药调整要点\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      老年人、新陈代谢变慢或肝肾功能不全时应调整剂量。比如，伊立替康在肝病患者中需减量，奥沙利铂肾损伤时须谨慎使用。孕妇及哺乳期妇女通常仅在医生严格评估后才考虑用药。对于营养状态不佳人群，部分化疗药可能更易出现副作用，需加强监护。正确做法：每次用药前均要核查肝肾功能，并根据报告调整药量，绝不可自行决定增减药物。\n    \u003C/p>\n    \u003Cp>\n      临床上，一位老年患者化疗期间，医生根据血肝功能监测多次调整伊立替康剂量，有效规避了重度副反应。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f7faf7 64%, #dce2e1 100%);\">\n    \u003Ch2>😕六、常见不良反应及处理方法\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      化疗药物常见的副作用包括恶心、呕吐、乏力、骨髓抑制（如白细胞下降）、口腔黏膜不适以及脱发。部分药物（如伊立替康）容易引起腹泻，奥沙利铂可能导致手足麻木、冷感。靶向药物如贝伐珠单抗有引发高血压或蛋白尿的风险。出现副作用时，应及时向医生反映，切勿擅自停药，可配合使用止吐药、护胃药等辅助药品。\u003Cspan style=\"color:#425066;font-style:italic;\">说明书提示：\u003C/span>伊立替康所致腹泻发生率约60%，需及时补液和用止泻药防止严重反应。（Sanoff, H.K., et al., 2009, Journal of Clinical Oncology）\n    \u003C/p>\n    \u003Cp>\n      正确做法：出现副作用时优先联系医师，必要时可先暂缓部分非核心药品，用支持药物辅助减轻症状。如发生发热、剧烈呕吐，应优先院内处理，不自行服用未确认药品。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f5faf8 60%, #ecf0ee 100%);\">\n    \u003Ch2>📦七、药品保存与过期处理\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      多数化疗药物以及靶向药品需要在阴凉、干燥处保存，优选2~8℃的冷藏环境，避免阳光暴晒和高温。口服片剂不可放在厨房、浴室等湿热地方；注射液开瓶后应按说明书规定时间内用完，如溶液改色或出现沉淀，务必弃用。过期药品不可擅自丢弃，建议按照社区指导交由专门处置单位处理，避免环境污染。\n    \u003C/p>\n    \u003Cp>\n      正确做法：每次取药后即冷藏，未用完的药物及时查看有效期，到期立即丢弃，不留存备用。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #e8f2f8 55%, #e0ecef 100%);\">\n    \u003Ch2>⚡八、漏服与过量用药处理方法\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      漏服口服化疗药时，推荐规则是：若时间相差不大，可尽快补服；如快到下次服药，跳过漏服不重复用药。静脉注射药一旦漏用，应报告医师，由医生重新安排补药时序。过量服药可能导致严重毒性反应，例如骨髓抑制、消化道症状加重等。若误服或超剂量静脉用药，应立即就医，不得延误。正确做法：设置提醒避免漏服，每次用药全程由家属或护理人员陪同监督。\n    \u003C/p>\n    \u003Cp>\n      一位患者因错过一次卡培他滨服药，及时联系医生后调整方案，未发生严重副作用，说明沟通和监控机制在用药安全中的重要性。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #e5ebf0 55%, #e0eaef 100%);\">\n    \u003Ch2>🎯九、药品使用指南总结与安全提醒\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cp>\n      结肠癌T3NxM1阶段涉及多种化疗与靶向药品，每一种药都有其特殊的应用时机和剂型要求。只要掌握了正确的服药方法、剂型处理技巧、避免药物相互作用、合理调整特殊人群剂量，定期监测身体反应并妥善保存药品，就能大提升用药安全性。有一点非常重要：任何疑问都应与专业医生沟通，切勿自行决策。守住安全底线，才能让药品效果最大化，远离用药失误风险。\n    \u003C/p>\n    \u003Cp>\n      记住，安全使用化疗和靶向药物，不仅能发挥药品的最大作用，也能保护你的健康和生活质量。关键信息包括：严守用药时间、按需调整剂量、发现不良反应立即上报、正确保存与处理药品、杜绝随意叠加其他药物。希望这份指南能帮你走好每一步。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 引用文献列表 -->\n\u003Cdiv class=\"colonguide-section\">\n  \u003Cdiv class=\"colonguide-header\" style=\"background: linear-gradient(90deg, #f7f9fc 65%, #e6e9ed 100%);\">\n    \u003Ch2>📚主要参考文献\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"colonguide-content\">\n    \u003Cul class=\"colonguide-refs\">\n      \u003Cli>Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., et al. (2016). Evolving role of chemotherapy and targeted therapies in metastatic colorectal cancer. \u003Ci>Journal of Clinical Oncology\u003C/i>, 34(9), 972-979.\u003C/li>\n      \u003Cli>Grothey, A., Sargent, D., Goldberg, R.M., Schmoll, H.J. (2018). Chemotherapy and targeted therapy combinations for colorectal cancer. \u003Ci>Nature Reviews Clinical Oncology\u003C/i>, 15, 409-424.\u003C/li>\n      \u003Cli>Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 350(23), 2335-2342.\u003C/li>\n      \u003Cli>Sanoff, H.K., Sargent, D.J., Campbell, M.E., Morton, R.F., Fuchs, C.S., et al. (2009). Five-year data and prognostic factor analysis of the N9741 phase III trial. \u003Ci>Journal of Clinical Oncology\u003C/i>, 27(26), 4301–4307.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.colonguide-title {\n  text-align: center;\n  padding: 28px 0 12px 0;\n  background: linear-gradient(90deg, #eff8fe 70%, #ddebed 100%);\n  border-radius: 10px;\n  margin-bottom: 18px;\n  font-family: \"Segoe UI\", Arial, sans-serif;\n}\n.colonguide-title h1 {\n  font-size: 38px;\n  color: #254971;\n  margin: 0 0 4px 0;\n}\n.colonguide-subtitle {\n  font-size: 22px;\n  color: #5379a0;\n  margin-bottom: 8px;\n  font-weight: 500;\n}\n.colonguide-section {\n  margin-bottom: 32px;\n  border-radius: 8px;\n  box-shadow: 0 2px 10px rgba(107,166,206,0.042);\n}\n.colonguide-header {\n  padding: 18px 22px;\n  border-radius: 8px 8px 0 0;\n  background-repeat: no-repeat;\n  background-size: cover;\n}\n.colonguide-header h2 {\n  font-size: 30px;\n  color: #2e4b6c;\n  margin: 0;\n  font-weight: 700;\n  text-shadow: 0 2px 3px rgba(204, 217, 226, 0.14);\n  letter-spacing: 0.5px;\n}\n.colonguide-content {\n  padding: 18px 26px 22px 26px;\n  background: #fff;\n  font-size: 18px;\n  color: #405066;\n  line-height: 1.9;\n  border-radius: 0 0 8px 8px;\n  font-family: \"Segoe UI\", Arial, sans-serif;\n}\n.colonguide-content p {\n  margin-bottom: 14px;\n}\n.colonguide-content ul.colonguide-refs {\n  padding-left: 16px;\n}\n.colonguide-content ul.colonguide-refs li {\n  font-size: 16px;\n  color: #3b4d5e;\n  margin-bottom: 8px;\n  line-height: 1.5;\n}\n.colonguide-note {\n  background: rgba(199, 222, 238, 0.12);\n  border-left: 4px solid #7aa2c0;\n  padding: 8px 14px;\n  border-radius: 6px;\n  color: #4472a6;\n  font-size: 16px;\n  margin-bottom: 12px;\n  font-style: italic;\n}\n@media (max-width: 800px) {\n  .colonguide-title h1 {\n    font-size: 25px;\n  }\n  .colonguide-header h2 {\n    font-size: 18px;\n  }\n  .colonguide-content {\n    font-size: 16px;\n    padding: 12px 12px 15px 12px;\n  }\n}\n\u003C/style>","\u003Cdiv id=\"material_title\" class=\"colonguide-title\">\n  \u003Ch1>结肠癌T3NxM1分期常用药品关键用法指南\u003C/h1>\n  \u003Cp class=\"colo",518,"2025-12-02 00:18:32","结肠癌, 化疗药物, 靶向药物, 用药指南, 副作用","掌握结肠癌T3NxM1分期化疗与靶向药物的关键用法、注意事项和不良反应处理，确保用药安全，提高治疗效果。","2025-12-31 21:05:43",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]